2 September 2016 in Chemical Reviews
15 April 2016 in Chemical Society Reviews
This review provides a panoramic sketch of the emergent researching field of building protein self-assembly systems based on supramolecular strategies.
18 July 2013 in Journal of the American Chemical Society
1 October 2010 in Molecular Pharmacology
Known agonists of the orphan receptor GPR35 are kynurenic acid, zaprinast, 5-nitro-2-(3-phenylproplyamino) benzoic acid, and lysophosphatidic acids. Their relatively low affinities for GPR35 and prominent off-target effects at other pathways, however, diminish their utility for understanding GPR35 signaling and for identifying potential therapeutic uses of GPR35. In a screen of the Prestwick Library of drugs and drug-like compounds, we have found that pamoic acid is a potent GPR35 agonist. Pamoic acid is considered by the Food and Drug Administration as an inactive compound that enables long-acting formulations of numerous drugs, such as the antihelminthics oxantel pamoate and pyrantel pamoate; the psychoactive compounds hydroxyzine pamoate (Vistaril) and imipramine pamoate (Tofranil-PM); and the peptide hormones triptorelin pamoate (Trelstar) and octreotide pamoate (OncoLar). We have found that pamoic acid induces a Gi/o-linked, GPR35-mediated increase in the phosphorylation of extracellular signal-regulated kinase 1/2, recruitment of β-arrestin2 to GPR35, and internalization of GPR35. In mice, it attenuates visceral pain perception, indicating an antinociceptive effect, possibly through GPR35 receptors. We have also identified in collaboration with the Sanford-Burnham Institute Molecular Libraries Probe Production Center new classes of GPR35 antagonist compounds, including the nanomolar potency antagonist methyl-5-[(tert-butylcarbamothioylhydrazinylidene)methyl]-1-(2,4-difluorophenyl)pyrazole-4-carboxylate (CID2745687). Pamoic acid and potent antagonists such as CID2745687 present novel opportunities for expanding the chemical space of GPR35, elucidating GPR35 pharmacology, and stimulating GPR35-associated drug development. Our results indicate that the unexpected biological functions of pamoic acid may yield potential new uses for a common drug constituent.
4 January 2017 in ACS Nano
31 July 2020 in Proceedings of the National Academy of Sciences
Significance: How does enamel achieve its remarkable microstructure? This study reveals that the cleaved enamel protein amelogenin adopts a ribbon-like supramolecular structure that controls the growth of mineral into nanofibers. Protein nanoribbons of 15 to 20 nm in width were identified in dental enamel and replicated from a recombinant protein mimicking an enzymatic cleavage product of human amelogenin. In mineralization experiments, these protein structures templated the growth of highly oriented apatite nanofibers along their backbone from an amorphous precursor. In accordance with the natural process of enamel development, this in vitro model suggests that the ability of amelogenin nanoribbons to guide fibrous apatite growth is regulated by enzymatic processing and their interaction with acidic nonamelogenin proteins in the developing enamel matrix.